Use of the medicine Alphagan®P in the treatment of paediatric glaucoma

Abstract

The article presents the experience of one of the modern anti-hypertensive medicine, approved for use in children, Alphagan® P in various forms, stages of congenital and secondary glaucoma in children. Data obtained in this study allowed us to estimate the effectiveness of the drug as monotherapy and in combined appointment, a comparative analysis of the degree of IOP reduction at different stages and forms of paediatric glaucoma, including young children.

Keywords

congenital glaucoma / secondary glaucoma / antiglaucomatous drugs / Alphagan-P® / intraocular pressure

References

[1] Аветисов Э.С., Ковалевский Е.И., Хватова А.В. Руководство по детской офтальмологию. М.: Медицина; 1987.

[2] Moore W., Nischal K.K. Pharmacologic management of glaucoma in childhood. Paediatr. Drugs. 2007; 9(2): 71-9.

[3] Coppens G., Stalmans I., Zeyen T., Casteels I. The safety and efficacy of glaucoma medication in the pediatric population. J. Pediatr. Ophthalmol. Strabismus. 2009. 46(1): 12-8.

[4] Daubert G.P. Is brimonidine ophthalmic a safe therapy for infants? J. Clin. Pharmacol. Ther 2006; 31(3): 289-92.

[5] Montero-de-Espinosa I., Marquez-de-Aracena R., Morales C. Ocular hypertension in children treated with brimonidine 0,2%. A clinical study. Arch. Soc. Esp. Oftalmol. 2006; 81(3): 155-9.

[6] Bowman R.J., Cope J., Nischal K.K. Ocular and systemic side effects of brimonidine 0,2% eye drops (Alphagan) in children. Eye (Lond). 2004; 18(1): 24-6.

RIGHTS & PERMISSIONS

Eco-Vector